ecancer posted on X:
“The Phase 3 SURPASS-ET trial evaluates ropeginterferon alfa-2b versus anagrelide in patients with essential thrombocythaemia. Ropeginterferon shows superior safety and efficacy compared to anagrelide.
Watch full interview with Dr Ruben Mesa.”
More posts featuring Ruben Mesa.